Clinical Trial Search

Primary: The Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS) Will be the Primary Outcome Measure — 15.25; 16.13 units on a scale

Primary: Yale Brown Obsessive Compulsive Scale (YBOCS) Modified for PSP (NE-YBOCS) — 18.8; 17.6; 16.1; 17.3 units on a scale

Primary: Percentage of Participants With ≥ 4- Point Decrease in 7-day Average Worst Itch - Numerical Rating Scale (WI-NRS) up to Week 14 — 24.24; 14.50 percentage of participants…

Primary: Percent Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) Score at Week 4. — -44.37; -50.37 percentage of change from…

Primary: Self-Injurious Thoughts and Behaviors Interview (SITBI) - Lifetime Episodes — 73.29; 0 episode count

Primary: Percent Increase in Glutathione (GSH) Concentrations in the ACC — 5; 0; 2 Percent change

Primary: SCORAD Change Score — 33.34 Change Score

Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58

Primary: Absolute NRS Itch Score at Week 16 (End of Treatment) — 7; 7.5 Units on a scale

Primary: Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale — 27.3; 44.4; 36.4 percentage of subjects

Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…

Primary: Phospho-erk (p-ERK) Levels of Target cNF Tumors in NFX-179 Gel Group and Vehicle Gel Group After 28 Days of Once-daily (QD) Application — 0.3054; 0.2734; 0.2267; 0.1627…

Primary: Numeric Rating Scale for Itch — 6.42; 7.8 score on a scale (0~10)

Primary: Massachusetts General Hospital Hair Pulling Scale (MGH-HPS) — 10.70; 13.53 units on a scale

Primary: Number of Patients Who Achieve at Least a 3-point Reduction in AI-NRS. — 1; 3 Participants — p=0.59

Primary: Social Processing (Cyberball) fMRI Task: fMRI Responses — -621.4739585; -519.1597701; -63.33972338; -396.4460666 beta-weight

Primary: Percent of Participants With Worst Itch Numeric Rating Scale (WI-NRS) 4-point Responder Rate at Week 10 — 18.95; 25.90; 81.05; 74.10 Percentage of participants — p=0.158

Primary: Percent of Subjects With Worst-Itch Numeric Rating Scale 4-point Responder at Week 10 — 26.45; 20.31 Percentage of subjects — p=0.229

Primary: Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17 — 8.4567; 4.2618 F/mm^2

Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019

Primary: Change in Mean Necrobiosis Lipoidica (NL) Lesion Score — -2.7 score on a scale — p=0.005

Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change

Primary: Clearance of SK Lesions — 82 percentage of SK lesion clearance

Primary: Number of Participants Enrolled Within One Year — 12; 11 Participants

Primary: Change in WI-NRS From Baseline to Week 6 — -2.25; -2.32; -2.01 score on a scale

Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants

Primary: Visual Analogue Scale (VAS) — 2.90; 3.29 score on a scale

Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters

Primary: Brain Activation Associated With the Resolution of Cognitive Conflict — .7; .59 Arbitrary units — p=0.0585

Primary: Average Visual Analog Scale at Baseline — 7.92; 7.88 Units on a scale